Painkiller maker Acura gets NIH grant

Share this article:

Painkiller manufacturer Acura Pharmaceuticals has scored a $300,000 grant from the National Institutes of Health to develop its Limitx technology, which is intended to make it harder to abuse hydrocodone pills when they are swallowed, or, as described in the company announcement “to deter abuse by excess oral consumption.”

The idea is that pills will release less hydrocodone if a user has swallowed multiple pills at once, and the company says initial tests in a simulated stomach indicate it has potential.

The company already has some abuse-deterrent platforms, such as its Aversion technology which turns crushed pain pills into an uninjectable mass. It also makes Impede, which irritates nasal passages, in the hope that it will make snorting an unpleasant experience. Early results indicated this was not the case, and the company expects to initiate a new clinical trial.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.